Sana Biotechnology (NASDAQ:SANA) Shares Down 4.1%

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) fell 4.1% during mid-day trading on Friday . The stock traded as low as $4.41 and last traded at $4.43. 286,001 shares changed hands during trading, a decline of 88% from the average session volume of 2,300,654 shares. The stock had previously closed at $4.62.

Analyst Upgrades and Downgrades

SANA has been the topic of a number of recent analyst reports. Citigroup upped their target price on Sana Biotechnology from $8.00 to $15.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Rodman & Renshaw started coverage on shares of Sana Biotechnology in a research report on Wednesday, June 26th. They set a “buy” rating and a $16.00 price target on the stock. Finally, HC Wainwright lowered their price objective on Sana Biotechnology from $12.00 to $11.00 and set a “buy” rating for the company in a report on Friday, August 9th.

Sana Biotechnology Stock Down 6.7 %

The company has a market capitalization of $954.68 million, a price-to-earnings ratio of -2.81 and a beta of 1.45. The stock has a 50 day simple moving average of $5.44 and a 200 day simple moving average of $7.12.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.04). As a group, analysts forecast that Sana Biotechnology, Inc. will post -1.13 EPS for the current year.

Institutional Trading of Sana Biotechnology

Hedge funds have recently bought and sold shares of the company. Algert Global LLC bought a new position in Sana Biotechnology in the 2nd quarter worth about $73,000. The Manufacturers Life Insurance Company increased its position in Sana Biotechnology by 8.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 312,031 shares of the company’s stock valued at $1,704,000 after acquiring an additional 23,157 shares during the period. Dark Forest Capital Management LP raised its stake in Sana Biotechnology by 112.0% during the 2nd quarter. Dark Forest Capital Management LP now owns 27,314 shares of the company’s stock valued at $149,000 after acquiring an additional 14,430 shares in the last quarter. Squarepoint Ops LLC boosted its position in Sana Biotechnology by 318.8% during the 2nd quarter. Squarepoint Ops LLC now owns 126,572 shares of the company’s stock worth $691,000 after acquiring an additional 96,348 shares during the period. Finally, Integral Health Asset Management LLC grew its stake in shares of Sana Biotechnology by 22.4% in the second quarter. Integral Health Asset Management LLC now owns 1,200,000 shares of the company’s stock worth $6,552,000 after purchasing an additional 220,000 shares in the last quarter. 88.23% of the stock is currently owned by institutional investors.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.